Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16711390rdf:typepubmed:Citationlld:pubmed
pubmed-article:16711390lifeskim:mentionsumls-concept:C0231337lld:lifeskim
pubmed-article:16711390lifeskim:mentionsumls-concept:C0029016lld:lifeskim
pubmed-article:16711390lifeskim:mentionsumls-concept:C0376515lld:lifeskim
pubmed-article:16711390lifeskim:mentionsumls-concept:C1709313lld:lifeskim
pubmed-article:16711390lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:16711390lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:16711390lifeskim:mentionsumls-concept:C0085752lld:lifeskim
pubmed-article:16711390lifeskim:mentionsumls-concept:C2728259lld:lifeskim
pubmed-article:16711390pubmed:issue10lld:pubmed
pubmed-article:16711390pubmed:dateCreated2006-5-22lld:pubmed
pubmed-article:16711390pubmed:abstractTextIntroduction of bcl-2 gene in EIA + c-Ha-ras-transformed rat embryo fibroblasts, which are unable to be arrested after damaging influences and possess high proapoptotic sensitivity, results not only in suppression of cell death but also in re-establishment of cell cycle block following DNA damage and serum starvation. Flow cytometry showed that E1A + c-Ha-ras + bcl-2-transformants treated with DNA-intercalator adriamycin are capable of being arrested at G1/S boundary for a long time (for less than 5 days). According to the growth curve data, the number of Bcl-2-overexpressing cells remanins constant for a week of cultivation with adriamycin. Clonogenic efficacy of E1A + c-Ha-ras + bcl-2-cells is brought to no already in 16 h after adriamycin addition. Apoptotic death, revealed by oligonucleosomic fragmentation of DNA, as well as cell death, occurring due to mitotic catastrophe, after adriamycin treatment are almost absent in Bcl-2-overexpressing transformants, as compared with parental E1A + c-Ha-ras-transformants. Bcl-2 introduction in E1A + c-Ha-ras-transformants is accompanied by a rise of SA beta-Gal (Senescence Associated beta-Galactosidase) activity, which is commonly considered to be a marker of cell senescence. Adriamycin treatment of E1A + c-Ha-ras + bcl-2-transformants results in a much higher rise in SA beta-Gal activity, as compared with untreated cells. Co-immunoprecipitation experiments demonstrated the introduction of Bcl-2 to result in formation of Bcl-2 complexes with early region E1A oncoproducts, which are thought to be responsible for proapoptotic susceptibility of E1A-expressing transformants. The data obtained lead to suggestion that bcl-2 transfer to E1A + c-Ha-ras-transformants may induce a switch from the cell death program on the program of senescence after DNA damage, due, presumably, to Bcl-2 interaction with the apoptosis activator the viral oncoprotein E1A.lld:pubmed
pubmed-article:16711390pubmed:languageruslld:pubmed
pubmed-article:16711390pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16711390pubmed:citationSubsetIMlld:pubmed
pubmed-article:16711390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16711390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16711390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16711390pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16711390pubmed:statusMEDLINElld:pubmed
pubmed-article:16711390pubmed:issn0041-3771lld:pubmed
pubmed-article:16711390pubmed:authorpubmed-author:PospelovV AVAlld:pubmed
pubmed-article:16711390pubmed:authorpubmed-author:PospelovaT...lld:pubmed
pubmed-article:16711390pubmed:authorpubmed-author:ZubovaS GSGlld:pubmed
pubmed-article:16711390pubmed:authorpubmed-author:AksenovN DNDlld:pubmed
pubmed-article:16711390pubmed:authorpubmed-author:NeliudovaA...lld:pubmed
pubmed-article:16711390pubmed:issnTypePrintlld:pubmed
pubmed-article:16711390pubmed:volume47lld:pubmed
pubmed-article:16711390pubmed:ownerNLMlld:pubmed
pubmed-article:16711390pubmed:authorsCompleteYlld:pubmed
pubmed-article:16711390pubmed:pagination907-16lld:pubmed
pubmed-article:16711390pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:meshHeadingpubmed-meshheading:16711390...lld:pubmed
pubmed-article:16711390pubmed:year2005lld:pubmed
pubmed-article:16711390pubmed:articleTitle[Antiapoptotic oncogene bcl-2 induces a program of senescence in E1A + c-Ha-ras-transformants treated with adriamycin].lld:pubmed
pubmed-article:16711390pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16711390pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:16711390pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed